PROactive Evaluation of Function to Avoid CardioToxicity (PROACT)
Sponsor: Myocardial Solutions
Terminated
Insufficient funding/staff
This PHASE2 trial investigates Breast Cancer and Cardiotoxicity and is currently terminated or withdrawn. Myocardial Solutions leads this study, which shows 19 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Terminated PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 14 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Terminated → Active Not Recruiting
-
Apr 2023 — Apr 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Apr 2019 — Oct 2019 [monthly]
Recruiting PHASE2
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Myocardial Solutions
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .